Pharmaceutical industry groups and companies asked the FDA to provide more specifics on when sponsors can rely on a single pivotal trial plus confirmatory evidence for approval of new drugs. The policy push seeks clearer guidance and examples that define “one trial enough,” aiming to reduce uncertainty in the evidence standards used for regulatory review. The request reflects continuing tension between speed and rigor in modern drug evaluation, especially as clinical trial designs evolve and sponsors look to manage timelines and development costs. For biotechs planning pivotal packages, the question is practical: regulatory clarity can change how programs are sized and how risk is buffered with confirmatory datasets. The filing also signals a broader industry push toward predictable regulatory pathways as companies increasingly blend real-world data, bridging studies, and postmarketing commitments into evidence strategies.